Apr 27, 2022
About the Company: For decades, clinicians have sought better treatment options for patients with brain tumors that would effectively target tumor cells while preserving eloquent tissue. Driven to overcome the limitations of current treatments and raise the standard of care, a group of brain tumor specialists joined forces to address this critical, unmet need. Together with medical device experts, they developed GammaTile Therapy, Surgically Targeted Radiation Therapy (STaRT) for recurrent intracranial neoplasms.
About Matthew Likens: Mr. Likens is an accomplished leader in the medical device industry. Prior to coming to GT Medical Technologies, he served as the president and chief executive officer of Ulthera, Inc. There, he led the startup from pre-commercialization to more than $100M in revenue and a $600M acquisition by Merz Pharma GmbH. Mr. Likens’ professional career began with Johnson & Johnson. However, he spent the bulk of his career at Baxter Healthcare Corporation, where he progressed through a variety of domestic and international sales, marketing, and general management roles that ultimately culminated in the position of president of Baxter Biotech North America, and then the president of its US Renal Care division. After leaving Merz in mid-2016, Mr. Likens eventually retired for 15 months before meeting the five founders of GT Medical in mid-2017. Mr. Likens is a member of the Greater Phoenix Economic Council Healthcare Innovation Committee and the City of Mesa Economic Development Advisory Board, as well as a member of the Kent State University College of Business Advisory Board. He joined GT Medical Technologies because he was inspired by the company’s powerful purpose of “Improving the lives of patients with brain tumors.”
To learn more about GT Medical's technology, please visit https://gtmedtech.com.
